serotonin reuptake inhibitor (SSRI)

PreclinicalSmall molecule

serotonin reuptake inhibitor (SSRI) is one of 27 small molecule programs targeting Premature Ejaculation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Premature EjaculationActive, not recruiting

Premature EjaculationPreclinical

Active, not recruiting

Competition

Competitive Landscape

38 competitors in Premature Ejaculation

#DrugCompanyPhaseTrials

Viagra

VViatris Specialty LLC

Approved

1 2

Xylocaine

MMEDRx USA, Inc.

Approved

1 3

Cialis

Eli Lilly

Phase 3

2 4

Paxil

SSebela Pharmaceuticals Development LLC

Phase 3

2 5

Restasis

TTaiwan Bio Therapeutics Inc.

Phase 3

2 6

Ultram

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

2 7

Botox

AbbVie

Phase 3

1 8

Rapaflo

AbbVie

Phase 2

1 9

Anafranil

SSpecgx

Phase 3

2 10

Standard Treatment

Boehringer Ingelheim

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ANot yet recruiting

Premature Ejaculation

NCT07067970

Clinical

Trials by Indication[1]

Pain Management1 trial

Effectiveness of Dry Needling Adjuvant to Selective Serotonin Reputake Inhibitors vs TP Injection for Pain Management

Active, not recruiting·SSuperior University·N/A·NCT06457581·35 enrolled

Premature Ejaculation1 trial

Comparison of the Efficacy and Safety of Dapoxetine, Kegel Exercises, and Acupuncture in the Treatment of Premature Ejaculation: A Randomized, Double-Blind, Placebo-Controlled Trial

Not yet recruiting·MMedipol University·N/A·NCT07067970·250 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for serotonin reuptake inhibitor (SSRI). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — serotonin reuptake inhibitor (SSRI) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for serotonin reuptake inhibitor (SSRI). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medipol University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMedipol University

serotonin reuptake inhibitor (SSRI)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Pain Management1 trial

Premature Ejaculation1 trial

References

Drug Info

Quick Facts

Related News